Cite
HARVARD Citation
Gerstein, H. et al. (2021). Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist. Diabetes, obesity & metabolism. 23 (2), pp. 318-323. [Online].